{"content":"<li class=\"n-box-item date-title\" data-end=\"1500695999\" data-start=\"1500609600\" data-txt=\"Monday, December 23, 2019\">Friday, July 21, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3280415\" data-ts=\"1500673306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280415-celsion-files-for-holders-to-offer-up-to-4_87m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion files for holders to offer up to 4.87M shares</a></h4><ul>   <li>Celsion (<a href=\"http://seekingalpha.com/symbol/CLSN\" target=\"_blank\">CLSN</a> <font color='red'>-3.7%</font>) is <font color='red'>down another 1.1%</font> after hours following the filing for its shareholders to <a href=\"https://seekingalpha.com/filing/3631707\" target=\"_blank\">offer up to 4.87M shares</a> of common stock, issuable upon exercise of certain outstanding common stock purchase warrants.</li>    <li>If the warrants are exercised in cash, the now-$7.6M company can see $16.6M in proceeds.</li>    <li>Selling stockholders are Sabby Management, Anson Investments Master Fund, and Intracoastal Capital. After the offering, Sabby and Anson will be beneficial owners of a 9.99% stake each, and Intracoastal of 6.45%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280415\" data-linked=\"Celsion files for holders to offer up to 4.87M shares\" data-tweet=\"$CLSN - Celsion files for holders to offer up to 4.87M shares https://seekingalpha.com/news/3280415-celsion-files-for-holders-to-offer-up-to-4_87m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3280415-celsion-files-for-holders-to-offer-up-to-4_87m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280414\" data-ts=\"1500673117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280414-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/WG' title='Willbros Group, Inc.'>WG</a> <font color='green'>+2.9%</font>. <a href='https://seekingalpha.com/symbol/HES' title='Hess Corporation'>HES</a> <font color='green'>+2.3%</font>. <a href='https://seekingalpha.com/symbol/KTEC' title='Key Technology, Inc.'>KTEC</a> <font color='green'>+1.8%</font>. <a href='https://seekingalpha.com/symbol/PRCP' title='Perceptron, Inc.'>PRCP</a> <font color='green'>+1.6%</font>. <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='green'>+1.5%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a> <font color='red'>-10.6%</font>. <a href='https://seekingalpha.com/symbol/BSBR' title='Banco Santander &#40;Brasil&#41; S.A.'>BSBR</a> <font color='red'>-2.2%</font>. <a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='red'>-2.0%</font>. <a href='https://seekingalpha.com/symbol/TERP' title='TerraForm Power, Inc.'>TERP</a> <font color='red'>-2.0%</font>. <a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='red'>-2.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280414\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$WG $HES $KTEC - After Hours Gainers / Losers https://seekingalpha.com/news/3280414-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3280414-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280401\" data-ts=\"1500668941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280401-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/REMX' title='VanEck Vectors Rare Earth/Strategic Metals ETF'>REMX</a> <font color='green'>+4.0%</font>. <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a> <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/SIVR' title='ETFS Physical Silver Trust ETF'>SIVR</a> <font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/PSLV' title='Sprott Physical Silver Trust'>PSLV</a> <font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/SLV' title='iShares Silver Trust ETF'>SLV</a> <font color='green'>+3.4%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='red'>-6.7%</font>. <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a> <font color='red'>-2.9%</font>. <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a> <font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a> <font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a> <font color='red'>-2.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280401\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$REMX $URA $SIVR - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3280401-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3280401-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280392\" data-ts=\"1500667179\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGY\" target=\"_blank\">EGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280392-vaalco-energy-forced-to-shut-in-well-offshore-gabon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vaalco Energy forced to shut-in well offshore Gabon</a></h4><ul>     <li>Vaalco Energy (<a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='red'>-2.2%</font>) is lower today after reporting it <a href=\"https://seekingalpha.com/pr/16892802-vaalco-provides-operational-update\" target=\"_blank\">shut in a well off Gabon</a> because of problems with the electrical submersible pump months after bringing it back online.</li>     <li>EGY says the electrical submersible pump in the South Tchibala 2-H well failed, resulting in the well being temporarily shut-in; the well was producing ~1,300 gross bbl/day of oil (390 bbl/day net to the company) before being shut-in.</li>     <li>EGY says it does not plan to change its annual production guidance as a result of the shut-in.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280392\" data-linked=\"Vaalco Energy forced to shut-in well offshore Gabon\" data-tweet=\"$EGY - Vaalco Energy forced to shut-in well offshore Gabon https://seekingalpha.com/news/3280392-vaalco-energy-forced-to-shut-in-well-offshore-gabon?source=tweet\" data-url=\"https://seekingalpha.com/news/3280392-vaalco-energy-forced-to-shut-in-well-offshore-gabon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280390\" data-ts=\"1500667163\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDRM\" target=\"_blank\">NDRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280390-deutsche-bank-likes-neuroderm-sees-42-upside-shares-ahead-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank likes NeuroDerm, sees 42% upside; shares ahead 7%</a></h4><ul><li>Deutsche Bank has initiated coverage on NeuroDerm (<a href='https://seekingalpha.com/symbol/NDRM' title='NeuroDerm'>NDRM</a> <font color='green'>+6.9%</font>) with a Buy rating and $47 (42% upside) price target, citing several key catalysts over the next 12 - 18 months.</li><li>It believes lead candidate, Phase 3-stage ND0612, could become the standard of care for advanced Parkinson's disease. Top-line data are expected next year.</li><li>Last month, there were rumors circulating that the company was considering selling itself.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3272929-neuroderm-mulling-sale-shares-12-percent\" target=\"_blank\">NeuroDerm mulling sale; shares up 12%</a> (June 12)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3247555-neuroderms-subcutaneously-delivered-ld-cd-successful-mid-stage-parkinsons-study\" target=\"_blank\">NeuroDerm's subcutaneously delivered LD/CD successful in mid-stage Parkinson's study</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280390\" data-linked=\"Deutsche Bank likes NeuroDerm, sees 42% upside; shares ahead 7%\" data-tweet=\"$NDRM - Deutsche Bank likes NeuroDerm, sees 42% upside; shares ahead 7% https://seekingalpha.com/news/3280390-deutsche-bank-likes-neuroderm-sees-42-upside-shares-ahead-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3280390-deutsche-bank-likes-neuroderm-sees-42-upside-shares-ahead-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280388\" data-ts=\"1500666025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMUS\" target=\"_blank\">TMUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280388-barclays-reiterates-t-mobile-market-weight-after-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays reiterates T-Mobile at Market Weight after results</a></h4><ul>   <li>T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color='green'>+2.3%</font>) has been reiterated at Market Weight by Barclays, which anticipates the carrier's string of solid results to continue as it waits for the prospect of a merger or buyout.</li>    <li>The <a href=\"https://seekingalpha.com/news/3279622-record-revenues-boost-t-mobile-substantial-q2-beat\" target=\"_blank\">company's results were strong</a> especially in the face of tough competition (unlimited plans from AT&amp;T and Verizon, and aggressive promotions from Sprint), the firm notes, but postpaid ARPU and service revenues were below Barclays' estimates.</li>    <li>Core EBITDA beat expectations, however. Barclays \"fine-tunes\" its 2017 estimates, trimming free cash flow expectations to $2.32B form $2.61B, and expecting net leverage of 3x, at the low end of a company target of 3-4x.</li>    <li>Barclays expects 2018 service revenues to rise 5.7% to $31.9B and core EBITDA to grow 11.1% to $11.04B, along with free cash flow of $3.32B.</li>    <li>The firm notes CEO John Legere taking a cautious stance on the prospect of merging with Sprint while still suggesting that a transaction between the two is viable.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280388\" data-linked=\"Barclays reiterates T-Mobile at Market Weight after results\" data-tweet=\"$TMUS - Barclays reiterates T-Mobile at Market Weight after results https://seekingalpha.com/news/3280388-barclays-reiterates-t-mobile-market-weight-after-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3280388-barclays-reiterates-t-mobile-market-weight-after-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280387\" data-ts=\"1500665832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNTA\" target=\"_blank\">MNTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280387-momenta-gets-good-new-bad-news-verdict-in-lovenox-patent-infringement-case-against\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Momenta gets good new/bad news verdict in Lovenox patent infringement case against Amphastar; -3%/+3%</a></h4><ul><li>Momenta Pharmaceuticals (<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='red'>-3.2%</font>) received a <a href=\"https://seekingalpha.com/pr/16893412-momenta-pharmaceuticals-announces-jury-verdict-enoxaparin-sodium-injection-patent-litigation\" target=\"_blank\">mixed decision</a> from a Massachusetts district court today regarding its litigation against Amphastar Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AMPH' title='Amphastar'>AMPH</a> <font color='green'>+2.7%</font>) over alleged infringement of a U.S. patent covering LOVENOX (enoxaparin sodium injection).</li><li>The jury found that the patent was infringed, but invalid and unenforceable.</li><li>CEO Craig Wheeler says, &ldquo;We are disappointed in the jury&rsquo;s verdict and believe the facts and the law do not support these findings. We are considering all available legal options to overturn the verdict, including post-trial motions and appeals. We continue to believe in the importance of investing in innovative techniques for bringing products to market and protecting those innovations from unauthorized use.&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"3280387\" data-linked=\"Momenta gets good new/bad news verdict in Lovenox patent infringement case against Amphastar; -3%/+3%\" data-tweet=\"$MNTA $MNTA $AMPH - Momenta gets good new/bad news verdict in Lovenox patent infringement case against Amphastar; -3%/+3% https://seekingalpha.com/news/3280387-momenta-gets-good-new-bad-news-verdict-in-lovenox-patent-infringement-case-against?source=tweet\" data-url=\"https://seekingalpha.com/news/3280387-momenta-gets-good-new-bad-news-verdict-in-lovenox-patent-infringement-case-against\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280385\" data-ts=\"1500664981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280385-ge-bull-throws-in-towel-oil-gas-weakness-outweighs-aerospace-health\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE bull throws in the towel, as oil/gas weakness outweighs aerospace/health</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-3.2%</font>) bounces off its worst levels but remains deep in the red after reporting better than expected <a href=\"https://seekingalpha.com/news/3280227-ge-beats-immelts-last-quarter\" target=\"_blank\">Q2 earnings</a> but <a href=\"https://seekingalpha.com/news/3280297-ge-minus-4_5-percent-open-immelt-warns-oil-gas-weakness\" target=\"_blank\">warning</a> of full-year profits at the low end of its forecasts.</li><li>Today's selloff would mark the <a href=\"http://www.marketwatch.com/story/ges-stock-tumbles-as-outgoing-ceo-immelt-ends-reign-with-dim-outlook-2017-07-21\" target=\"_blank\">eighth straight quarter</a> that GE shares&nbsp;declined on the day earnings results were reported.</li>     <li>CFRA analyst Jim Corridore <a href=\"http://www.barrons.com/articles/ge-another-bull-bites-the-dust-1500658100\" target=\"_blank\">throws in the towel</a>, downgrading shares to Hold from Buy, cutting his price target to $27 from $36 as well as his 2018 EPS estimate to $1.80 from a previous forecast of $1.85.</li>     <li>&ldquo;With oil and gas weakness overshadowing strength in aerospace and health, we now think there are better investment choices with likely higher EPS growth prospects in the industrial sector,&rdquo; Corridore writes.</li>     <li>GE today reaffirmed its 2017 forecasts for cash flow, profit, revenue and operating margins, but investors will have to wait for incoming CEO John Flannery to deliver an update on 2018 forecasts later this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280385\" data-linked=\"GE bull throws in the towel, as oil/gas weakness outweighs aerospace/health\" data-tweet=\"$GE - GE bull throws in the towel, as oil/gas weakness outweighs aerospace/health https://seekingalpha.com/news/3280385-ge-bull-throws-in-towel-oil-gas-weakness-outweighs-aerospace-health?source=tweet\" data-url=\"https://seekingalpha.com/news/3280385-ge-bull-throws-in-towel-oil-gas-weakness-outweighs-aerospace-health\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280380\" data-ts=\"1500663657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280380-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ATHN' title='athenahealth, Inc.'>ATHN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SSNT' title='SilverSun Technologies, Inc.'>SSNT</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/EGOV' title='NIC Inc.'>EGOV</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/MANH' title='Manhattan Associates, Inc.'>MANH</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NCR' title='NCR Corporation'>NCR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280380\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$PLUG $SITO $ANY - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3280380-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3280380-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280378\" data-ts=\"1500662248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HBAN\" target=\"_blank\">HBAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280378-huntington-bancsharesminus-4-after-q2-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huntington Bancshares -4% after Q2 beat</a></h4><ul><li>Q2 adjusted EPS of $0.26 topped estimates by three cents. Many metrics aren't don't make for a great comparison to last &nbsp;year thanks to the FirstMerit acquisition.</li><li>Net interest margin of 3.31% up 25 basis points Y/Y.</li><li>Net charge-offs as a percentage of average loans of 0.21% vs. long-term target range of 0.35%-0.55%. Nonperforming asset ratio of 0.61% vs. 0.93% a year ago; auto loans doing fine, with net charge-offs down 16 basis points from Q1 to 0.29%.</li><li>Speaking on the earnings call, CEO Steve Steinour takes note of the flattening yield curve as taking away some of the benefits of the Fed's rate hikes.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280232-huntington-bancshares-beats-0_03-beats-revenue\" target=\"_blank\">Huntington Bancshares beats by $0.03, beats on revenue</a> (July 21)</li><li><a href='https://seekingalpha.com/symbol/HBAN' title='Huntington Bancshares Incorporated'>HBAN</a>&nbsp;<font color='red'>-4.2%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3280378\" data-linked=\"Huntington Bancshares -4% after Q2 beat\" data-tweet=\"$HBAN - Huntington Bancshares -4% after Q2 beat https://seekingalpha.com/news/3280378-huntington-bancsharesminus-4-after-q2-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3280378-huntington-bancsharesminus-4-after-q2-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280377\" data-ts=\"1500661714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECA\" target=\"_blank\">ECA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280377-encanaplus-3-following-strong-q2-production-growth-surges\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Encana +3% following strong Q2 as production growth surges</a></h4><ul>     <li>Encana (<a href='https://seekingalpha.com/symbol/ECA' title='Encana Corporation'>ECA</a> <font color='green'>+2.7%</font>) enjoys strong gains after reporting a <a href=\"https://seekingalpha.com/news/3280184-encana-eps-0_34\" target=\"_blank\">strong Q2</a> that included a US$331M net profit vs. a US$601M net loss in the year-ago quarter.</li>     <li>ECA says it now expects year-end 2017 production from its core operations in the Montney and Duvernay in western Canada and the Eagle Ford and Permian in the U.S. to <a href=\"http://www.cbc.ca/news/canada/calgary/encana-q2-2017-profit-report-1.4215788\" target=\"_blank\">finish 25%-30% above</a> last year's end-of-year level, better than its previously estimated outlook for growth of 20% or better.</li>     <li>Q2 core asset production was 246.5K boe/day, up by 9.2K boe/day from the prior quarter; total Q2 output was 316K boe/day, with oil and liquids volumes accounting for ~40% of the total production mix vs. 35% during Q1.</li>     <li>Q2 non-GAAP corporate margin of $12.19/boe was up 25% Q/Q despite lower benchmark commodity prices.</li>     <li>ECA says it plans to leave its 2017 capital budget at $1.6B-$1.8B despite recent oil price volatility.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280377\" data-linked=\"Encana +3% following strong Q2 as production growth surges\" data-tweet=\"$ECA - Encana +3% following strong Q2 as production growth surges https://seekingalpha.com/news/3280377-encanaplus-3-following-strong-q2-production-growth-surges?source=tweet\" data-url=\"https://seekingalpha.com/news/3280377-encanaplus-3-following-strong-q2-production-growth-surges\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280375\" data-ts=\"1500660510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUAN\" target=\"_blank\">NUAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280375-nuance-rebounding-after-malware-incident-prompts-preliminary-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nuance rebounding after malware incident prompts preliminary miss</a></h4><ul>   <li>Nuance Communications (<a href=\"http://seekingalpha.com/symbol/NUAN\" target=\"_blank\">NUAN</a> <font color='green'>+2.7%</font>) has rebounded from a premarket depression caused by <a href=\"https://seekingalpha.com/pr/16893116-nuance-provides-update-malware-incident-business-impact\" target=\"_blank\">preliminary Q3 results</a> that showed the lingering effects of a malware incident from last month.</li>    <li>The company says Q3's coming in at EPS of $0.26-$0.28, below consensus for $0.31, and with lower than expected revenues. It's releasing full results <a href=\"https://seekingalpha.com/pr/16893112-nuance-release-third-quarter-fiscal-2017-results-tuesday-august-8-2017\" target=\"_blank\">after the close on Aug. 8</a>.</li>    <li>Net new bookings are up 20-25%, though, attributed to growth in Dragon Medical cloud, voice biometrics solutions, the automotive business, and Enterprise omni-channel offerings.</li>    <li>The company expects to restore service to \"substantially all\" clients on its flagship eScription LH platform within two weeks.</li>    <li>It could still face \"significant\" headwinds in Q4, Stifel Nicolaus says.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280258-trading-nuance-suspended-pending-news\" target=\"_blank\">Trading in Nuance suspended pending news</a> (Jul. 21 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280375\" data-linked=\"Nuance rebounding after malware incident prompts preliminary miss\" data-tweet=\"$NUAN - Nuance rebounding after malware incident prompts preliminary miss https://seekingalpha.com/news/3280375-nuance-rebounding-after-malware-incident-prompts-preliminary-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3280375-nuance-rebounding-after-malware-incident-prompts-preliminary-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280373\" data-ts=\"1500660186\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280373-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TTI' title='Tetra Technologies Inc.'>TTI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SPN' title='Superior Energy Services, Inc.'>SPN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SXT' title='Sensient Technologies Corporation'>SXT</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280373\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$TTI $FMSA $WMLP-OLD - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3280373-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3280373-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280369\" data-ts=\"1500658550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANET\" target=\"_blank\">ANET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280369-arista-networksminus-2_3-will-appeal-itc-decision-build-workarounds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arista Networks -2.3%; will appeal ITC decision, build workarounds</a></h4><ul>   <li>Arista Networks (NYSE:<a href='https://seekingalpha.com/symbol/ANET' title='Arista Networks, Inc.'>ANET</a>) is <font color='red'>down 2.3%</font> today after a <a href=\"https://seekingalpha.com/news/3280124-arista-minus-4_3-percent-itc-keeps-cisco-related-import-ban-place\" target=\"_blank\">setback at the ITC</a>, which maintained an import ban on products involved in a patent dispute with Cisco Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>).</li>    <li>That's despite rulings by the Patent Trial and Appeal Board that invalidated a pair of Cisco's related patents. Those actions aren't a final step, the ITC noted.</li>    <li>In a statement, Arista said it was \"deeply disappointed\" in the decision, which represented an \"unfortunate departure from precedent and from the core premise of the America Invents Act and its inter partes review proceedings.\" It's appealing the decision and working on modified products in case the ITC decision is sustained.</li>    <li>The move brings \"<a href=\"http://www.barrons.com/articles/arista-sags-q3-uncertainty-rises-with-itc-setback-says-wells-fargo-1500648735\" target=\"_blank\">near-term execution risk</a>\" for Arista that could affect the Q3 outlook, says Wells Fargo's Jess Lubert. Meanwhile, J.P. Morgan's Rod Hall imagines Arista is ready with workarounds: \"In the end of the day this is disappointing for Arista and likely sustains margin pressure from US production. However, we believe the positive PTAB ruling was a surprise and that Arista is likely well prepared to continue to operate given this outcome.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280369\" data-linked=\"Arista Networks -2.3%; will appeal ITC decision, build workarounds\" data-tweet=\"$ANET $ANET $CSCO - Arista Networks -2.3%; will appeal ITC decision, build workarounds https://seekingalpha.com/news/3280369-arista-networksminus-2_3-will-appeal-itc-decision-build-workarounds?source=tweet\" data-url=\"https://seekingalpha.com/news/3280369-arista-networksminus-2_3-will-appeal-itc-decision-build-workarounds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280368\" data-ts=\"1500658199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FITB\" target=\"_blank\">FITB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280368-fifth-third-up-3-after-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fifth Third up 3% after Q2 results</a></h4><ul><li>The banks are mostly lower today, but Fifth Third (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color='green'>+3.1%</font>) is an outlier to the upside after Q2 EPS of $0.45 topped estimates by two cents.</li><li>Net interest margin of 3.01% was up 16 basis points from one year ago and inline with estimates.</li><li>Helping was better than hoped-for loan performance, with net charge-offs of $64M down $25M from Q1 and $23M from a year ago. Estimates had called for NCOs to be about flat.</li><li>Provisions of $52M fell from $74M in Q1 and $91M a year ago. Estimates had called for about a flat read from a year ago.</li><li>Tangible book value per share of $17.11 gained 1% from Q1 and 1% from a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280196-fifth-third-bancorp-beats-0_02-misses-revenue\" target=\"_blank\">Fifth Third Bancorp beats by $0.02, misses on revenue</a> (July 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280368\" data-linked=\"Fifth Third up 3% after Q2 results\" data-tweet=\"$FITB - Fifth Third up 3% after Q2 results https://seekingalpha.com/news/3280368-fifth-third-up-3-after-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3280368-fifth-third-up-3-after-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280363\" data-ts=\"1500656743\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280363-financials-top-5-gainers-losers-of-1-05-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:05 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/INDB' title='Independent Bank Corp.'>INDB</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CHCT' title='Community Healthcare Trust'>CHCT</a> <font color='green'>+8%</font>.<a href='https://seekingalpha.com/symbol/COF' title='Capital One Financial Corporation'>COF</a> <font color='green'>+8%</font>. WMIH <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/INBK' title='First Internet Bancorp'>INBK</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/BLX' title='Banco Latinoamericano De Comercio Exterior, S.A.'>BLX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RCG' title='RENN Global Entrepreneurs Fund'>RCG</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280363\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:05 PM\" data-tweet=\"$INDB $CHCT $COF - Financials - Top 5 Gainers / Losers as of 1:05 PM https://seekingalpha.com/news/3280363-financials-top-5-gainers-losers-of-1-05-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3280363-financials-top-5-gainers-losers-of-1-05-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280359\" data-ts=\"1500656154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280359-eros-international-halted-after-20-drop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros International halted after 20% drop</a></h4><ul>     <li>Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) is halted on NYSE, hitting a circuit breaker after <font color='red'>plunging 20%</font>.</li>     <li>Shares had run from $8.80 to $13.90 from June 8 to this Wednesday before dropping 2% yesterday.</li>     <li>The stock has been hit this year with accusations of accounting fraud, and shares dropped in March after film delays spurred short reports raising <a href=\"https://seekingalpha.com/news/3252776-eros-international-minus-6_4-percent-film-delay-stirs-liquidity-talk\" target=\"_blank\">concerns about liquidity</a>.</li>   <li><b>Updated 1:01 p.m.:</b> Shares are <font color='red'>-15.8%</font> in resumed trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280359\" data-linked=\"Eros International halted after 20% drop\" data-tweet=\"$EROS - Eros International halted after 20% drop https://seekingalpha.com/news/3280359-eros-international-halted-after-20-drop?source=tweet\" data-url=\"https://seekingalpha.com/news/3280359-eros-international-halted-after-20-drop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280358\" data-ts=\"1500656106\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280358-national-beverage-pauses-after-credit-suisse-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage pauses after Credit Suisse downgrade</a></h4><ul><li>Too far, too fast, says analyst Laurent Grandet of National Beverage's (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>) more than&nbsp;<font color='green'>100% YTD gain</font>.</li><li>Grandet expects a growth slowdown for the LaCroix brand, which makes up 50%-60% of company sales, noting \"limited distribution headroom.\"</li><li>Competition is also on the rise, threatening LaCroix's market-leading 25% share of the sparkling water business.</li><li>He downgrades to Underperform from Neutral. The unchanged price target of $82 suggests about 20% downside.</li><li>Shares are&nbsp;<font color='red'>lower today by 5.3%</font>&nbsp;to $102.53.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280358\" data-linked=\"National Beverage pauses after Credit Suisse downgrade\" data-tweet=\"$FIZZ - National Beverage pauses after Credit Suisse downgrade https://seekingalpha.com/news/3280358-national-beverage-pauses-after-credit-suisse-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3280358-national-beverage-pauses-after-credit-suisse-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280356\" data-ts=\"1500655685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280356-chipotle-extends-losses-analysts-weigh-in-nowminus-12-this-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle extends losses as more analysts weigh in; now -12% this week</a></h4><ul>     <li>Chipotle Mexican Grill (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='red'>-2.5%</font>) slides to a new 52-week low, capping a nightmare week that has seen shares drop 12%.</li>     <li>Argus <a href=\"http://thefly.com/thestreet/realmoney/index.php/CMGid2581725/CMG-Chipotle-downgraded-to-Hold-from-Buy-at-Argus\" target=\"_blank\">downgrades</a> shares to Hold from Buy, as <a href=\"https://seekingalpha.com/news/3279217-chipotle-shuts-restaurant-customers-become-ill-shares-minus-4-percent\" target=\"_blank\">this week's norovirus outbreak</a> at a Virginia restaurant likely will hurt sales, operating margins and the stock's current lofty valuation; the firm cuts its FY 2017 EPS estimate to $8.10 from $9.00 and FY 2018 to $12 from $12.50.</li>     <li>Canaccord cuts its stock price target to $400 from $440, believing CMG's sales recovery will now be <a href=\"https://www.streetinsider.com/Analyst+Comments/Chipotle+Mexican+Grill+%28CMG%29+PT+Lowered+to+%24400+at+Canaccord+Genuity%3B+PressSocial+Media+Coverage+of+Norovirus+Event+Provide+On-Going+Risk/13118292.html\" target=\"_blank\">slower than expected</a>, as \"minor issues, such as the recent norovirus event, will continue to be magnified by the press and social media.\"</li>     <li>Nomura cuts its 2017 EPS forecast to $7.65 from $8.30 and its 2018 EPS view to $11 from $12, and <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9806045/chipotles-sss-targets-may-be-history-after-horrendous-we\" target=\"_blank\">slashed its stock price by nearly $100</a> to $385 from $480.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280356\" data-linked=\"Chipotle extends losses as more analysts weigh in; now -12% this week\" data-tweet=\"$CMG - Chipotle extends losses as more analysts weigh in; now -12% this week https://seekingalpha.com/news/3280356-chipotle-extends-losses-analysts-weigh-in-nowminus-12-this-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3280356-chipotle-extends-losses-analysts-weigh-in-nowminus-12-this-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280353\" data-ts=\"1500655451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280353-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='green'>+99%</font>. <a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-54%</font>. <a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/OFLX' title='Omega Flex, Inc.'>OFLX</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/AMSC' title='American Superconductor Corporation'>AMSC</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EGOV' title='NIC Inc.'>EGOV</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/MANH' title='Manhattan Associates, Inc.'>MANH</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280353\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$TEAR $ANY $EKSO - Midday Gainers / Losers https://seekingalpha.com/news/3280353-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3280353-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280352\" data-ts=\"1500654610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLB\" target=\"_blank\">SLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280352-schlumberger-s-solid-q2-fails-to-boost-oil-services-peers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schlumberger\u2019s solid Q2 fails to boost oil services peers</a></h4><ul>     <li>Schlumberger (<a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a> <font color='red'>-0.6%</font>) kicked off Q2 oil service earnings, beating expectations with a <a href=\"https://seekingalpha.com/news/3280242-schlumberger-posts-q2-beat-buy-majority-stake-eurasia-drilling\" target=\"_blank\">generally positive take</a> on the domestic and international markets, but it is not enough to provide a boost in trading for the broader sector as investors focus on the macro environment.</li><li>Piper Jaffray analyst Bill Herbert sees Q2 results as \"considerably better\" than expectations but free cash flow was the \"lone blemish\" in the quarter.</li><li>Wells Fargo's Jud Bailey says SLB&rsquo;s strong North American results are positive for peers including Halliburton (<a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color='red'>-1.6%</font>), as well as small-cap servicers such as C&amp;J&nbsp;Energy (<a href='https://seekingalpha.com/symbol/CJ' title='C&J Energy Services, Inc.'>CJ</a> <font color='red'>-5.3%</font>), RPC&nbsp;Inc. (<a href='https://seekingalpha.com/symbol/RES' title='RPC Inc.'>RES</a> <font color='red'>-2.9%</font>), Superior Energy Services (<a href='https://seekingalpha.com/symbol/SPN' title='Superior Energy Services, Inc.'>SPN</a> <font color='red'>-6.4%</font>) and Keane Group (<a href='https://seekingalpha.com/symbol/FRAC' title='Keane Group'>FRAC</a> <font color='red'>-3.8%</font>).</li><li>Seaport Global's Mike Urban thinks SLB's signs of life in international markets are a very positive read-through for HAL, but SLB is being \"mum on the macro,\" which investors could interpret negatively.</li><li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280352\" data-linked=\"Schlumberger\u2019s solid Q2 fails to boost oil services peers\" data-tweet=\"$SLB $SLB $HAL - Schlumberger\u2019s solid Q2 fails to boost oil services peers https://seekingalpha.com/news/3280352-schlumberger-s-solid-q2-fails-to-boost-oil-services-peers?source=tweet\" data-url=\"https://seekingalpha.com/news/3280352-schlumberger-s-solid-q2-fails-to-boost-oil-services-peers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280345\" data-ts=\"1500653070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280345-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MNRO' title='Monro, Inc.'>MNRO</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ALV' title='Autoliv Inc.'>ALV</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GNTX' title='Gentex Corporation'>GNTX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/AXL' title='American Axle & Manufacturing Holdings, Inc.'>AXL</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280345\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$MNRO $ALV $GNTX - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3280345-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3280345-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280334\" data-ts=\"1500651466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISRG\" target=\"_blank\">ISRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280334-sell-siders-bullish-on-intuitive-surgical-after-q2-beat-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-siders bullish on Intuitive Surgical after Q2 beat; shares down 4%</a></h4><ul><li>On cue, sell-side shops make bullish revisions to their models for Intuitive Surgical (<a href='https://seekingalpha.com/symbol/ISRG' title='Intuitive Surgical, Inc.'>ISRG</a> <font color='red'>-3.5%</font>) after it posted better-than-expected Q2 numbers.</li><li>Stifel: price target raised to $1,100 from $850 based on upward revision to procedure growth.</li><li>RBC Capital: price target raised to $1,000 from $950 citing pipeline progress and accelerating robotics adoption.</li><li>Cantor: price target raised to $1,050 from $1,000.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280041-intuitive-surgical-q2-top-line-13-percent-earnings-20-percent-shares-1-percent-hours\" target=\"_blank\">Intuitive Surgical Q2 top line up 13%; earnings up 20%; shares up 1% after hours</a> (July 20)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280024-intuitive-surgical-beats-0_16-beats-revenue\" target=\"_blank\">Intuitive Surgical beats by $0.16, beats on revenue</a> (July 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280334\" data-linked=\"Sell-siders bullish on Intuitive Surgical after Q2 beat; shares down 4%\" data-tweet=\"$ISRG - Sell-siders bullish on Intuitive Surgical after Q2 beat; shares down 4% https://seekingalpha.com/news/3280334-sell-siders-bullish-on-intuitive-surgical-after-q2-beat-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3280334-sell-siders-bullish-on-intuitive-surgical-after-q2-beat-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280333\" data-ts=\"1500650795\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMPI\" target=\"_blank\">DMPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280333-delmar-pharma-poised-to-continue-valminus-083-stoked-up-move-shares-ahead-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DelMar Pharma poised to continue VAL-083-stoked up move; shares ahead 19%</a></h4><ul><li>Thinly traded nano cap DelMar Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a> <font color='green'>+19.3%</font>) heads north on more than an 18x surge in volume. Shares were up over 44% before retracing. The stock is trying to break out of a brief consolidation after its rally in late June when the company announced that it was about to start a Phase 3 clinical trial assessing lead candidate VAL-083 in treatment-resistant brain cancer.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275018-delmar-go-start-late-stage-study-lead-product-candidate-valminus-083-shares-ahead-8-percent\" target=\"_blank\">DelMar on go to start late-stage study of lead product candidate VAL-083; shares ahead 8% premarket</a> (June 22)</li><li>See important&nbsp;<a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280333\" data-linked=\"DelMar Pharma poised to continue VAL-083-stoked up move; shares ahead 19%\" data-tweet=\"$DMPI - DelMar Pharma poised to continue VAL-083-stoked up move; shares ahead 19% https://seekingalpha.com/news/3280333-delmar-pharma-poised-to-continue-valminus-083-stoked-up-move-shares-ahead-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3280333-delmar-pharma-poised-to-continue-valminus-083-stoked-up-move-shares-ahead-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280327\" data-ts=\"1500649610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COO\" target=\"_blank\">COO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280327-keybanc-says-cooper-bit-pricey-shares-ease-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyBanc says Cooper a bit pricey; shares ease 2%</a></h4><ul><li>The market's red day is not helping Cooper Companies (<a href='https://seekingalpha.com/symbol/COO' title='The Cooper Companies Inc.'>COO</a> <font color='red'>-2.4%</font>). Shares are down, albeit on light volume, on the heels of a downgrade by KeyBance to Neutral.</li><li>Analyst Matt Mishan says any upward momentum will be stymied due to \"too much complacency\" in its valuation, adding that its current market cap has priced in solid fundamentals and above-market growth and is apparently discounting its inconsistent execution and long-term rotation risks in the space.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3280327\" data-linked=\"KeyBanc says Cooper a bit pricey; shares ease 2%\" data-tweet=\"$COO - KeyBanc says Cooper a bit pricey; shares ease 2% https://seekingalpha.com/news/3280327-keybanc-says-cooper-bit-pricey-shares-ease-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3280327-keybanc-says-cooper-bit-pricey-shares-ease-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280300\" data-ts=\"1500649400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280300-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='green'>+83%</font>. <a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+17%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280300\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$TEAR $DMPI $EKSO - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3280300-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3280300-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280325\" data-ts=\"1500649285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNI\" target=\"_blank\">MNI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280325-mcclatchyminus-2_1-print-ad-slowdown-continues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McClatchy -2.1% as print ad slowdown continues</a></h4><ul>   <li>McClatchy (NYSEMKT:<a href='https://seekingalpha.com/symbol/MNI' title='The McClatchy Company'>MNI</a>) is <font color='red'>off 2.1%</font> after posting <a href=\"https://seekingalpha.com/news/3280278-mcclatchy-reports-q2-results\" target=\"_blank\">Q2 earnings</a> where revenues slipped 7% amid a continuing drop in traditional print ads.</li>    <li>A net loss of $37.4M included impairments of $28.8M tied to the carrying value of interest in CareerBuilder and other investments; it posted an adjusted net loss of $6.1M, amounting to $0.80/share, missing expectations for a loss of $0.60/share (one estimate).</li>    <li>Declines in advertising slowed but continued due to ongoing softness in traditional print advertising.</li>    <li>Digital-only ad revenues grew 10%; total digital ad revenues (where the company includes digital bundled as a print advertising upsell) fell 0.9%.</li>    <li>Revenue breakout: Advertising, $125.2M (down 11.1%); Audience, $89.92M (down 0.6%); other, $9.97M (down 8.2%).</li>    <li>Average total unique visitors to online products were 66M (up 14.6%), and local unique visitors were 16.3M (up 10.7%). Mobile users made up 60.2% of average total unique visitors, vs. a year-ago 52.9%.</li>    <li><a href=\"http://www.mcclatchy.com/\" target=\"_blank\">Conference call</a> to come at noon ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16893204-mcclatchy-reports-second-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3280325\" data-linked=\"McClatchy -2.1% as print ad slowdown continues\" data-tweet=\"$MNI - McClatchy -2.1% as print ad slowdown continues https://seekingalpha.com/news/3280325-mcclatchyminus-2_1-print-ad-slowdown-continues?source=tweet\" data-url=\"https://seekingalpha.com/news/3280325-mcclatchyminus-2_1-print-ad-slowdown-continues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280322\" data-ts=\"1500648823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280322-surging-euro-puts-dent-in-european-shares-germany-down-nearly-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Surging euro puts dent in European shares; Germany down nearly 2%</a></h4><ul><li>Mario Draghi and the ECB sounded unexpectedly dovish this week, but that hasn't slowed the major rally in the euro (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXE' title='CurrencyShares Euro Trust ETF'>FXE</a>). It&nbsp;<font color='green'>jumped more than 1%</font>&nbsp;vs. the dollar yesterday, and is&nbsp;<font color='green'>higher by another 0.25%</font>&nbsp;today to $1.661 - up more than a dime since the start of the year, and the strongest since early 2015.</li><li>European shares are taking notice, with the Stoxx 600&nbsp;<font color='red'>down 1.2%</font>, led by the Dax's (NYSEARCA:<a href='https://seekingalpha.com/symbol/EWG' title='iShares MSCI Germany ETF'>EWG</a>)&nbsp;<font color='red'>1.95% selloff</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXE' title='CurrencyShares Euro Trust ETF'>FXE</a>, <a href='https://seekingalpha.com/symbol/VGK' title='Vanguard FTSE Europe ETF'>VGK</a>, <a href='https://seekingalpha.com/symbol/EUO' title='ProShares UltraShort Euro ETF'>EUO</a>, <a href='https://seekingalpha.com/symbol/HEDJ' title='WisdomTree Europe Hedged Equity ETF'>HEDJ</a>, <a href='https://seekingalpha.com/symbol/FEZ' title='SPDR EURO STOXX 50 ETF'>FEZ</a>, <a href='https://seekingalpha.com/symbol/IEV' title='iShares Europe ETF'>IEV</a>, <a href='https://seekingalpha.com/symbol/ERO' title='iPath EUR/USD Exchange Rate ETN'>ERO</a>, <a href='https://seekingalpha.com/symbol/EZU' title='iShares MSCI Eurozone ETF'>EZU</a>, <a href='https://seekingalpha.com/symbol/EPV' title='ProShares UltraShort FTSE Europe ETF'>EPV</a>, <a href='https://seekingalpha.com/symbol/EURL' title='Direxion Daily FTSE Europe Bull 3x Shares ETF'>EURL</a>, <a href='https://seekingalpha.com/symbol/DRR' title='Market Vectors Double Short Euro ETN'>DRR</a>, <a href='https://seekingalpha.com/symbol/FEU' title='SPDR STOXX Europe 50 ETF'>FEU</a>, <a href='https://seekingalpha.com/symbol/IEUR' title='iShares Core MSCI Europe ETF'>IEUR</a>, <a href='https://seekingalpha.com/symbol/DBEU' title='Deutsche X-trackers MSCI Europe Hedged Equity ETF'>DBEU</a>, <a href='https://seekingalpha.com/symbol/ULE' title='ProShares Ultra Euro ETF'>ULE</a>, <a href='https://seekingalpha.com/symbol/EUFX' title='ProShares Short Euro ETF'>EUFX</a>, <a href='https://seekingalpha.com/symbol/EEA' title='European Equity Fund'>EEA</a>, <a href='https://seekingalpha.com/symbol/HEZU' title='iShares Currency Hedged MSCI EMU ETF'>HEZU</a>, <a href='https://seekingalpha.com/symbol/FEP' title='First Trust Europe AlphaDEX ETF'>FEP</a>, <a href='https://seekingalpha.com/symbol/FEEU' title='Barclays ETN+ FI Enhanced Europe 50 ETN'>FEEU</a>, <a href='https://seekingalpha.com/symbol/URR' title='Market Vectors Double Long Euro ETN'>URR</a>, <a href='https://seekingalpha.com/symbol/UPV' title='ProShares Ultra FTSE Europe ETF'>UPV</a>, <a href='https://seekingalpha.com/symbol/ADRU' title='BLDRS Europe 100 ADR Index ETF'>ADRU</a>, <a href='https://seekingalpha.com/symbol/FIEU' title='Credit Suisse FI Enhanced Europe 50 ETN'>FIEU</a>, <a href='https://seekingalpha.com/symbol/HFEZ' title='SPDR Euro Stoxx 50 Currency Hedged ETF'>HFEZ</a>, <a href='https://seekingalpha.com/symbol/DBEZ' title='Deutsche X-trackers MSCI EMU Hedged Equity ETF'>DBEZ</a>, <a href='https://seekingalpha.com/symbol/FEUZ' title='First Trust Eurozone AlphaDex ETF'>FEUZ</a>, <a href='https://seekingalpha.com/symbol/FIEE' title='UBS AG FI Enhanced Europe 50 ETN'>FIEE</a>, <a href='https://seekingalpha.com/symbol/HGEU' title='ProShares Hedged FTSE Europe ETF'>HGEU</a>, <a href='https://seekingalpha.com/symbol/DEZU' title='iShares Adaptive Currency Hedged MSCI Eurozone ETF'>DEZU</a>, <a href='https://seekingalpha.com/symbol/GSEU' title='Goldman Sachs ActiveBeta Europe Equity ETF'>GSEU</a>, <a href='https://seekingalpha.com/symbol/HFXE' title='IQ 50 Percent Hedged FTSE Europe ETF'>HFXE</a>, <a href='https://seekingalpha.com/symbol/PTEU' title='Pacer Trendpilo European Index ETF'>PTEU</a>, <a href='https://seekingalpha.com/symbol/RFEU' title='First Trust RiverFront Dynamic Europe ETF'>RFEU</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3280322\" data-linked=\"Surging euro puts dent in European shares; Germany down nearly 2%\" data-tweet=\"$FXE $EWG $VGK - Surging euro puts dent in European shares; Germany down nearly 2% https://seekingalpha.com/news/3280322-surging-euro-puts-dent-in-european-shares-germany-down-nearly-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3280322-surging-euro-puts-dent-in-european-shares-germany-down-nearly-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280315\" data-ts=\"1500648808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTX\" target=\"_blank\">PTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280315-pernix-refinances-cash-resources-sufficient-to-fund-operations-through-2019-shares-down-13-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pernix refinances, cash resources sufficient to fund operations through 2019; shares down 13% on weak Q2 results</a></h4><ul><li>Pernix Therapeutics (<a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-13.1%</font>), still under pressure from its disappointing preliminary Q2 results, <a href=\"https://seekingalpha.com/pr/16892818-pernix-commences-refinancing-transactions-fortify-balance-sheet\" target=\"_blank\">announces</a> a series of refinancing transactions that it says will shore up its balance sheet and extend its cash runway through 2019.</li><li>A new $40M asset-backed credit revolver to refinance the Wells Fargo credit facility has been set up in addition to a $45M delayed-draw term loan (immediate access to $30M with an additional $15M available for certain acquisition purposes).</li><li>About $52M of its 4.25% convertible senior notes owned by institutional investors will be exchanged for ~$36M of new exchangeable notes (4.25%/5.25%) and ~1.1M shares of common stock at $5.50 per share. The transactions should close today.</li><li>The deals will provide the company with ~$63M in total liquidity, including $42M of cash and cash equivalents and $21M available under the revolver.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280120-pernix-sees-drop-revenues-q2-shares-slip-5-percent-hours\" target=\"_blank\">Pernix sees drop in revenues for Q2; shares slip 5% after hours</a> (July 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280315\" data-linked=\"Pernix refinances, cash resources sufficient to fund operations through 2019; shares down 13% on weak Q2 results\" data-tweet=\"$PTX $PTX-OLD - Pernix refinances, cash resources sufficient to fund operations through 2019; shares down 13% on weak Q2 results https://seekingalpha.com/news/3280315-pernix-refinances-cash-resources-sufficient-to-fund-operations-through-2019-shares-down-13-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3280315-pernix-refinances-cash-resources-sufficient-to-fund-operations-through-2019-shares-down-13-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280313\" data-ts=\"1500647560\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOV\" target=\"_blank\">KTOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280313-kitov-clawing-back-from-equity-offering-related-down-move-shares-up-over-60-since-last-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kitov clawing back from equity offering-related down move; shares up over 60% since last week</a></h4><ul><li>Investors in thinly traded nano cap Kitov Pharmaceuticals Holdings (<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+13.9%</font>) have been on a rollercoaster the past two weeks. Shares ran up as much as 80% in the two days prior to its announcement of a public equity offering. Shares promptly sold off, dropping almost 46% on the news.</li><li>Shares have regained the loss, up over 60% since bottoming at $1.27 on July 11. Two days ago, it <a href=\"https://seekingalpha.com/pr/16889104-kitov-announces-results-study-demonstrating-ntminus-219-enhanced-efficacy-keytruda-immune\" target=\"_blank\">announced </a>that subsidiary TyrNovo's lead candidate NT-219, combined with Merck's Keytruda (pembrolizumab), converted non-responding tumors into responders and blocked tumor progression in a preclinical model. No responses were observed with Keytruda alone or with NT-219 alone. The company intends to advance the candidate into clinical studies as soon as possible.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277914-kitov-prices-direct-equity-offering-shares-34-percent\" target=\"_blank\">Kitov prices direct equity offering; shares down 34%</a> (July 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280313\" data-linked=\"Kitov clawing back from equity offering-related down move; shares up over 60% since last week\" data-tweet=\"$KTOV - Kitov clawing back from equity offering-related down move; shares up over 60% since last week https://seekingalpha.com/news/3280313-kitov-clawing-back-from-equity-offering-related-down-move-shares-up-over-60-since-last-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3280313-kitov-clawing-back-from-equity-offering-related-down-move-shares-up-over-60-since-last-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280298\" data-ts=\"1500644684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAAP\" target=\"_blank\">AAAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280298-european-advisory-group-backs-approval-of-11-new-meds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs approval of 11 new meds</a></h4><ul><li>The European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/07/news_detail_002778.jsp&amp;mid=WC0b01ac058004d5c1\" target=\"_blank\">adopts positive opinions</a> backing the approval of 11 new therapies, including five Orphan Drugs:</li><li>Orphan Drug tagged <strong>Verkazia </strong>(ciclosporin) for the treatment of severe vernal keratoconjunctivitis in children and adolescents. Developed by Finnish drugmaker Santen Oy.</li><li>Orphan Drug-tagged <strong>Bavencio</strong> (avelumab), from Merck Serono Europe Limited, for the treatment of Merkel cell carcinoma.</li><li>Orphan Drug-tagged <strong>Lutathera </strong>(lutetium oxodotreotide), from Advanced Accelerator Applications (<a href='https://seekingalpha.com/symbol/AAAP' title='Advanced Accelerator Applications'>AAAP</a>), for the treatment of gastro-entero-pancreatic neurocrine tumors.</li><li>Orphan Drug-tagged <strong>Rydapt </strong>(midostaurin), from Novartis Europharm (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='red'>-0.5%</font>), for adults with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive, adults with aggressive systemic mastocytosis or mast cell leukemia.</li><li>Orphan Drug-tagged <strong>Xermelo </strong>(telotristat ethyl), from Ipsen Pharma (<a href='https://seekingalpha.com/symbol/IPSEY' title='Ipsen S.A. ADR'>OTCPK:IPSEY</a>) for carcinoid syndrome.</li><li><strong>Dupixent </strong>(dupilumab) for atopic dermatitis - Sanofi-Aventis (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='red'>-0.6%</font>).</li><li><strong>Symtuza </strong>(darunavir/cobicistat/emtricitabine) for HIV infection - Johnson &amp; Johnson's Janssen-Cilag International N.V. (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='red'>-0.7%</font>).</li><li><strong>Tecentriq </strong>(atezolizumab) for bladder cancer and non-small lung cancer - Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>).</li><li>Three generic meds: <strong>Entecavir Accord</strong> (entecavir) from Accord Healthcare, <strong>Entecavir Mylan</strong> (entecavir) from Mylan S.A.S. (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-0.9%</font>), both for hepatitis B infection and <strong>Lacosamide Accord</strong> (lacosamide) for epilepsy from Accord Healthcare.</li><li>Final decisions from the European Commission usually take ~60 days.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280298\" data-linked=\"European advisory group backs approval of 11 new meds\" data-tweet=\"$AAAP $AAAP $NVS - European advisory group backs approval of 11 new meds https://seekingalpha.com/news/3280298-european-advisory-group-backs-approval-of-11-new-meds?source=tweet\" data-url=\"https://seekingalpha.com/news/3280298-european-advisory-group-backs-approval-of-11-new-meds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280297\" data-ts=\"1500644354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280297-geminus-4_5-open-immelt-warns-on-oil-and-gas-weakness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE -4.5% at the open as Immelt warns on oil and gas weakness</a></h4><ul><li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-4.5%</font>) opens deep in the red, reversing initial premarket gains on news of the company's <a href=\"https://seekingalpha.com/news/3280227-ge-beats-immelts-last-quarter\" target=\"_blank\">Q2 earnings beat</a>, as a closer inspection of the results sends shares to their <a href=\"http://www.marketwatch.com/story/ges-stock-turns-sharply-lower-after-ceo-immelt-gives-downbeat-outlook-on-conference-call-2017-07-21\" target=\"_blank\">lowest since October 2015</a>.</li><li>Outgoing CEO&nbsp;Jeff Immelt, hosting his last earnings conference call, said the recovery for the oil and gas market has been slower and  more volatile than expected, and he  expects results for GE's legacy business to be \"<a href=\"http://www.marketwatch.com/story/ges-stock-turns-sharply-lower-after-ceo-immelt-gives-downbeat-outlook-on-conference-call-2017-07-21\" target=\"_blank\">lower than previously  anticipated</a>... Given our outlook on oil and gas, we are trending to the bottom end of  the range of $1.60-$1.70 EPS for the year.\"</li><li>Morgan Stanley analyst Nigel Coe notes Q2 power margins fell by 240 bps to 14.8% despite stronger revenues; with  power orders down 1% on a fairly undemanding comp, it reinforces the  notion that power is a significant driver of the EPS reset that is  expected next year, Coe says.</li><li>Q2 oil and gas margins fell by 490 bps to 5%, although likely affected by some  one-off factors, but \"it is clear that Power and O&amp;G estimates will come under pressure,\"&nbsp;Coe says.</li><li>Cowen&rsquo;s Gautam Khanna says GE's Q2 beat was led by non-operating items, with  very soft industrial free cash flow that will now require a huge H2 to  hit guidance.</li><li>Source:&nbsp;Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3280297\" data-linked=\"GE -4.5% at the open as Immelt warns on oil and gas weakness\" data-tweet=\"$GE - GE -4.5% at the open as Immelt warns on oil and gas weakness https://seekingalpha.com/news/3280297-geminus-4_5-open-immelt-warns-on-oil-and-gas-weakness?source=tweet\" data-url=\"https://seekingalpha.com/news/3280297-geminus-4_5-open-immelt-warns-on-oil-and-gas-weakness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280293\" data-ts=\"1500643708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280293-grouponminus-1_8-bofa-restarts-underperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon -1.8% as BofA restarts at Underperform</a></h4><ul>   <li>Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) is <font color='red'>down 1.8%</font> premarket as BofA Merrill Lynch reinstates the stock at Underperform ahead of earnings.</li>    <li>Shares have run <font color='green'>up 15.4%</font> YTD. BofA rejoins three other firms in ranking Groupon as a Sell.</li>    <li>The firm's set a price target of $3.50, implying 8.6% downside from yesterday's close.</li>    <li>Groupon's set to report before the opening bell Aug. 2.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280293\" data-linked=\"Groupon -1.8% as BofA restarts at Underperform\" data-tweet=\"$GRPN - Groupon -1.8% as BofA restarts at Underperform https://seekingalpha.com/news/3280293-grouponminus-1_8-bofa-restarts-underperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3280293-grouponminus-1_8-bofa-restarts-underperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280287\" data-ts=\"1500643200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280287-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a>&nbsp;<font color='green'>+16%</font>&nbsp;on announcing a special committee to consider and&nbsp;evaluate various strategic and financing alternatives.</li>     <li><a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='green'>+15%</font>&nbsp;on Wal-Mart <a href=\"https://seekingalpha.com/news/3280228-plug-power-14-percent-new-wal-mart-deal\" target=\"_blank\">deal</a>.</li>     <li><a href='https://seekingalpha.com/symbol/BCLI' title='BrainStorm Cell Therapeutics Inc.'>BCLI</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3280215-brainstorm-nabs-16m-cirm-grant-support-late-stage-nurown-study-shares-ahead-6-percent\" target=\"_blank\">receiving</a> CIRM grant of $16M to support late-stage NurOwn study.</li>     <li><a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='green'>+7%</font>&nbsp;on Buy <a href=\"https://seekingalpha.com/news/3280245-premarket-analyst-action-healthcare\" target=\"_blank\">rating</a> from Deutsche Bank.</li>     <li><a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280287\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$AEZS $PLUG $BCLI - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3280287-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3280287-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280285\" data-ts=\"1500642760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRAY\" target=\"_blank\">VRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280285-viewray-still-under-pressure-shares-down-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViewRay still under pressure, shares down 11% premarket</a></h4><ul><li>ViewRay (NASDAQ:<a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a>) is poised to add to yesterday's&nbsp;<font color='red'>8%</font>&nbsp;drop on almost a four-fold increase in volume. Shares are down&nbsp;<font color='red'>11%</font>&nbsp;premarket on modestly higher volume.</li><li>Yesterday, short seller Mako Research published a <a href=\"https://seekingalpha.com/article/4089011-viewray-initiate-strong-sell-questionable-backlog-product-inferiority-bankruptcy-concerns\" target=\"_blank\">report </a>on Seeking Alpha citing aging technology, a weak competitive position and the dubious background of certain people behind the stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280285\" data-linked=\"ViewRay still under pressure, shares down 11% premarket\" data-tweet=\"$VRAY - ViewRay still under pressure, shares down 11% premarket https://seekingalpha.com/news/3280285-viewray-still-under-pressure-shares-down-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3280285-viewray-still-under-pressure-shares-down-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280284\" data-ts=\"1500642641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZTO\" target=\"_blank\">ZTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280284-zto-express-sued-for-false-statements-in-u-s-ipo-sharesminus-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ZTO Express sued for false statements in U.S. IPO; shares -5%</a></h4><ul>     <li>ZTO Express (NYSE:<a href='https://seekingalpha.com/symbol/ZTO' title='ZTO Express'>ZTO</a>) <font color='red'>-5%</font> premarket following a Reuters report that the company and the underwriters of its NYSE listing have been sued by a U.S. pension fund <a href=\"https://www.reuters.com/article/us-zto-ipo-lawsuit-idUSKBN1A609Z\" target=\"_blank\">alleging profit margins were exaggerated</a> to lure investors into its $1.4B&nbsp;IPO.</li>     <li>Morgan Stanley and Goldman Sachs are named in the class-action lawsuit filed in Alabama state court by the city of Birmingham's pension fund, which says the underwriters failed to perform adequate due diligence.</li><li>ZTO's listing was the largest U.S. listing in 2016 and was the biggest  by a Chinese company since Alibaba's $25B IPO in 2014.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280284\" data-linked=\"ZTO Express sued for false statements in U.S. IPO; shares -5%\" data-tweet=\"$ZTO - ZTO Express sued for false statements in U.S. IPO; shares -5% https://seekingalpha.com/news/3280284-zto-express-sued-for-false-statements-in-u-s-ipo-sharesminus-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3280284-zto-express-sued-for-false-statements-in-u-s-ipo-sharesminus-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280283\" data-ts=\"1500642622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280283-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-43%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16893163-dryships-inc-reports-updated-key-financial-information-post-reverse-stock-split\" target=\"_blank\">reporting</a> financial information post reverse stock split.</li><li><a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='red'>-11%</font>.</li><li><a href='https://seekingalpha.com/symbol/ALV' title='Autoliv Inc.'>ALV</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3280199-autoliv-misses-0_06-misses-revenue\" target=\"_blank\">Q2 earnings</a> miss.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3280283\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$DRYS $VRAY $ALV - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3280283-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3280283-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280274\" data-ts=\"1500642115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETFC\" target=\"_blank\">ETFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280274-e-trade-up-3-after-beat-and-buyback-announcement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">E*Trade up 3% after beat and buyback announcement</a></h4><ul><li>After items, net income of $143M or $0.52 per share vs. $145M and $0.48 one year ago. Expectations had been for $0.48.</li><li>There was some good news on the credit front, where the company booked a $99M benefit to loan loss provisions thanks to the outperformance (vs. expectations) of loans as they converted from interest-only to amortizing.</li><li>Thanks to a lower leverage ratio threshold, the company announces a $1B buyback program.</li><li><a href='https://seekingalpha.com/symbol/ETFC' title='E*TRADE Financial Corporation'>ETFC</a>&nbsp;<font color='green'>+3%</font>&nbsp;premarket</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280025-e-trade-financial-beats-0_04-beats-revenue\" target=\"_blank\">E*TRADE Financial beats by $0.04, beats on revenue</a> (July 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280274\" data-linked=\"E*Trade up 3% after beat and buyback announcement\" data-tweet=\"$ETFC - E*Trade up 3% after beat and buyback announcement https://seekingalpha.com/news/3280274-e-trade-up-3-after-beat-and-buyback-announcement?source=tweet\" data-url=\"https://seekingalpha.com/news/3280274-e-trade-up-3-after-beat-and-buyback-announcement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280271\" data-ts=\"1500641819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAH\" target=\"_blank\">CAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280271-cardinal-health-to-explore-strategic-alternatives-china-big-growth-driver\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardinal Health to explore strategic alternatives, China a big growth driver</a></h4><ul><li>Cardinal Health (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a>) says it has begun the process of assessing strategic alternatives to support its next growth phase. Front and center is China, but the company admits that it will take capital investments and other resources to build out the business. It says that it is in discussions about its China operations, including Cordis and will be adding resources throughout the Asia-Pacific region once its acquisition of Medtronic's Patient Recovery business closes.</li><li>Shares are down a fraction premarket but only on 110 shares.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3280271\" data-linked=\"Cardinal Health to explore strategic alternatives, China a big growth driver\" data-tweet=\"$CAH - Cardinal Health to explore strategic alternatives, China a big growth driver https://seekingalpha.com/news/3280271-cardinal-health-to-explore-strategic-alternatives-china-big-growth-driver?source=tweet\" data-url=\"https://seekingalpha.com/news/3280271-cardinal-health-to-explore-strategic-alternatives-china-big-growth-driver\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280270\" data-ts=\"1500641811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANW\" target=\"_blank\">ANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280270-aegean-marine-promotes-mcilroy-to-president\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aegean Marine promotes Mcilroy to President</a></h4><ul>     <li>Aegean Marine Petroleum (<a href='https://seekingalpha.com/symbol/ANW' title='Aegean Marine Petroleum Network Inc.'>OTC:ANW</a>) <font color='green'>+2.9%</font> premarket after appointing Global Trading Manager Jonathan Mcilroy as its <a href=\"https://seekingalpha.com/pr/16892716-aegean-marine-petroleum-network-inc-announces-executive-leadership-changes\" target=\"_blank\">new President</a>, effective immediately.</li>     <li>Mcilroy has nearly 25 years of experience in the shipping, energy and bunker trading markets; he joined ANW in January 2016.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280270\" data-linked=\"Aegean Marine promotes Mcilroy to President\" data-tweet=\"$ANW - Aegean Marine promotes Mcilroy to President https://seekingalpha.com/news/3280270-aegean-marine-promotes-mcilroy-to-president?source=tweet\" data-url=\"https://seekingalpha.com/news/3280270-aegean-marine-promotes-mcilroy-to-president\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280268\" data-ts=\"1500641431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMCI\" target=\"_blank\">SMCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280268-super-micro-computer-plunges-after-preliminary-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Super Micro Computer plunges after preliminary Q4 results</a></h4><ul><li>        Super Micro Computer (NASDAQ:<a href='https://seekingalpha.com/symbol/SMCI' title='Super Micro Computer, Inc.'>SMCI</a>) shares take a beating in following yesterday&rsquo;s aftermarket reveal of preliminary <a href=\"https://seekingalpha.com/filing/3630444\" target=\"_blank\">Q4 results</a>.</li><li>               Super Micro Computer expects Q4 revenue between $712M and $717M, up from the previous guidance of $655M to $715M. Analyst consensus estimates put revenue at $682.03M.&nbsp;</li><li>               Diluted EPS expected between $0.35 and $0.37 compared to the $0.45 consensus.&nbsp;</li><li>               The company attributes the $0.09 negative impact on DRAM and SSD price increases and R&amp;D expenses.&nbsp;</li><li>               Super Micro Computer shares are&nbsp;<font color='red'>down 11.81%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3280268\" data-linked=\"Super Micro Computer plunges after preliminary Q4 results\" data-tweet=\"$SMCI - Super Micro Computer plunges after preliminary Q4 results https://seekingalpha.com/news/3280268-super-micro-computer-plunges-after-preliminary-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3280268-super-micro-computer-plunges-after-preliminary-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280259\" data-ts=\"1500639903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNTX\" target=\"_blank\">GNTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280259-on-gentexs-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Gentex&#39;s Q2</a></h4><ul>     <li>Gentex (NASDAQ:<a href='https://seekingalpha.com/symbol/GNTX' title='Gentex Corporation'>GNTX</a>)&nbsp;reports Automotive net sales rose 5% to $433.9M in <a href=\"https://seekingalpha.com/pr/16893114-gentex-reports-second-quarter-2017-financial-results\" target=\"_blank\">Q2</a>, due to 6% rise in auto-dimming mirror unit shipments .</li>     <li>Total auto-dimming mirror units +521 Y/Y to 9,788.</li>     <li>Gross margin rate squeezed 170 bps to 37.7%&nbsp;due to annual customer price reductions.</li>     <li>Operating margin rate declined 200 bps to 28.4%.</li>     <li><b>FY2017 Guidance</b>: Net sales: $1.79B to $1.83B; Gross margin rate: 38.5% to 39%; Operating expense: $165M to $170M; Tax rate: 31.5% to 32.5%; Capex: $115M to $130M; D&amp;A: $95M to $105M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280259\" data-linked=\"More on Gentex&#39;s Q2\" data-tweet=\"$GNTX - More on Gentex&#39;s Q2 https://seekingalpha.com/news/3280259-on-gentexs-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3280259-on-gentexs-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280258\" data-ts=\"1500639833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUAN\" target=\"_blank\">NUAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280258-trading-in-nuance-suspended-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading in Nuance suspended pending news</a></h4><ul><li>Nasdaq has halted trading in Nuance Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/NUAN' title='Nuance Communications, Inc.'>NUAN</a>) pending the release of news.</li><li>Preliminary fiscal Q3 EPS is $0.26 - 0.28 on revenues of $494M - 498M. Consensus is EPS of $0.29 on revs of ~$510M.</li><li><strong>Update</strong>: Trading to resume at 8:30 am ET.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>3%</font>&nbsp;on resumption of trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280258\" data-linked=\"Trading in Nuance suspended pending news\" data-tweet=\"$NUAN - Trading in Nuance suspended pending news https://seekingalpha.com/news/3280258-trading-in-nuance-suspended-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3280258-trading-in-nuance-suspended-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280253\" data-ts=\"1500639337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSU\" target=\"_blank\">KSU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280253-on-kansas-city-southerns-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Kansas City Southern&#39;s Q2</a></h4><ul>     <li>Kansas City Southern (NYSE:<a href='https://seekingalpha.com/symbol/KSU' title='Kansas City Southern'>KSU</a>)&nbsp;reports carload volume rose 6% to 567.1K in <a href=\"https://seekingalpha.com/pr/16893089-kansas-city-southern-reports-record-second-quarter-2017-revenues-earnings-per-share-time\" target=\"_blank\">Q2</a>.</li>     <li>Revenue by segment: Chemical &amp; Petroleum: $138.8M (+13%);&nbsp;Industrial &amp; Consumer Products: $148.6M (+9%);&nbsp;Agriculture &amp; Minerals: $123.4M (+7%); Energy: $70.5M (+90%); Intermodal: $90.6M (-1%); Automotive: $57.5M (+29%), Other: $27M (+24%).</li>     <li>Revenue per carload/unit increased 9% to $1,110.</li>     <li>Operating income grew 9% Y/Y to $239.3M.</li>     <li>KSU&nbsp;<font color='red'>-0.74%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280253\" data-linked=\"More on Kansas City Southern&#39;s Q2\" data-tweet=\"$KSU - More on Kansas City Southern&#39;s Q2 https://seekingalpha.com/news/3280253-on-kansas-city-southerns-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3280253-on-kansas-city-southerns-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280245\" data-ts=\"1500638417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPLO\" target=\"_blank\">DPLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280245-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Diplomat Pharmacy (NYSE:<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy'>DPLO</a>) initiated with Buy rating and $19.75 (27% upside) price target.</li><li>Express Scripts (NASDAQ:<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a>) initiated with Hold rating by Needham.</li><li>NeuroDerm (NASDAQ:<a href='https://seekingalpha.com/symbol/NDRM' title='NeuroDerm'>NDRM</a>) initiated with Buy rating and $47 (52% upside) price target. Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li><li>TherapeuticsMD (NYSEMKT:<a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a>) initiated with Buy rating at Deutsche Bank. Shares up&nbsp;<font color='green'>7%</font>&nbsp;premarket.</li><li>Revance Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a>) initiated with Overweight rating and $50 (119% upside) price target by Cantor Fitzgerald.</li><li>Repligen (NASDAQ:<a href='https://seekingalpha.com/symbol/RGEN' title='Repligen Corporation'>RGEN</a>) initiated with Outperform rating by William Blair.</li><li>CRH Medical (NYSEMKT:<a href='https://seekingalpha.com/symbol/CRHM' title='CRH Medical Corp.'>CRHM</a>) upgraded to Outperform by RBC.</li><li>Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) reiterated at Outperform with a $150 (10% upside) price target.</li><li>Cooper Companies (NYSE:<a href='https://seekingalpha.com/symbol/COO' title='The Cooper Companies Inc.'>COO</a>) downgraded to Sector Weight by Keybanc.</li><li>FibroGen (NASDAQ:<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a>) downgraded to Neutral with a $31 (11% downside risk) price target by Goldman Sachs. Shares are down&nbsp;<font color='red'>4%</font>&nbsp;premarket.</li><li>Ironwood Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IRWD' title='Ironwood Pharmaceuticals, Inc.'>IRWD</a>) downgraded to Neutral with a $19 (11% downside risk)&nbsp;price target by JPMorgan. Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket.</li><li>Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) downgraded to Underweight with a $113 (17% downside risk) price target by Atlantic. Downgraded to Sell with a $110 (19% downside risk) price target by BTIG Research citing a bearish outlook for pharmaceuticals, limited long-term value from Actelion and an overdue mean reversion of valuation compared to its peer group. Shares are down&nbsp;<font color='red'>1%&nbsp;</font>premarket but very light volume.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3280245\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$DPLO $DPLO $ESRX - Premarket analyst action - healthcare https://seekingalpha.com/news/3280245-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3280245-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280242\" data-ts=\"1500637860\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLB\" target=\"_blank\">SLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280242-schlumberger-posts-q2-beat-to-buy-majority-stake-in-eurasia-drilling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schlumberger posts Q2 beat; to buy majority stake in Eurasia Drilling</a></h4><ul>     <li>Schlumberger (NYSE:<a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a>) <font color='green'>+1.7%</font>&nbsp;premarket as <a href=\"https://seekingalpha.com/news/3280211-schlumberger-beats-0_05-beats-revenue\" target=\"_blank\">Q2 earnings</a> rose 40% Q/Q and beat analyst expectations, as beyond seasonal effects, revenue increased in all units and geographic areas.</li>     <li>SLB says Q2 North America revenue rose 18% following rapid deployment of idle hydraulic fracturing capacity; U.S. land revenue jumped 42% Q/Q, nearly double the 23% increase in land rig count, driven primarily by a 68% gain in hydraulic fracturing revenue as completions activity intensified and pricing continued to improve.</li>     <li>SLB says the H2 outlook for North America remains strong, but it is also seeing positive signs in international markets with rising activity and new project plans emerging in several markets.</li>     <li>Separately, SLB <a href=\"http://www.nasdaq.com/article/schlumberger-to-acquire-51-stake-in-eurasia-drilling-company---quick-facts-20170721-00287\" target=\"_blank\">agrees to acquire</a> a 51% stake in Russia's Eurasia Drilling for an undisclosed sum; SLB's attempt to buy a 45% stake in Eurasia for ~$1.7B in 2015 fell apart after deal approval was postponed several times by Russian regulators.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280242\" data-linked=\"Schlumberger posts Q2 beat; to buy majority stake in Eurasia Drilling\" data-tweet=\"$SLB - Schlumberger posts Q2 beat; to buy majority stake in Eurasia Drilling https://seekingalpha.com/news/3280242-schlumberger-posts-q2-beat-to-buy-majority-stake-in-eurasia-drilling?source=tweet\" data-url=\"https://seekingalpha.com/news/3280242-schlumberger-posts-q2-beat-to-buy-majority-stake-in-eurasia-drilling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280237\" data-ts=\"1500637273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFRG\" target=\"_blank\">DFRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280237-del-friscos-restaurant-down-on-earnings-miss-and-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Del Frisco&#39;s Restaurant down on earnings miss and guidance cut</a></h4><ul>     <li>Del Frisco's Restaurant (NASDAQ:<a href='https://seekingalpha.com/symbol/DFRG' title='Del Frisco&#39;s Restaurant Group'>DFRG</a>) reports total comparable restaurant sales declined 2.2%&nbsp;in <a href=\"https://seekingalpha.com/pr/16893043-del-frisco-s-restaurant-group-inc-announces-second-quarter-2017-results\" target=\"_blank\">Q2</a>, comprised of a 0.1% decrease in average check and 2.1% decrease in customer counts.</li>     <li>Comp decreased 5.2% at&nbsp;Sullivans Steakhouse, 0.5% at&nbsp;Del&nbsp;Frisco's&nbsp;Double Eagle Steak House and 3.2%&nbsp;at Del Friscos Grille.</li>     <li>Del Frisco's&nbsp;Double Eagle Steak House revenue rose 5.9% to $40.19M.</li>     <li>Sullivan's Steakhouse revenues squeezed 11.1% to $15.62M.</li>     <li>Del Frisco's Grille revenues grew 8.6% to $26.49M.</li>     <li>Restaurant-level EBITDA as a percentage of sales fell 90 bps to 20.5%.</li>     <li>G&amp;A expense rate -30 bps to 7.2%.</li>     <li><b>FY2017 Guidance</b>: Comparable restaurant sales: -2% to -1%;&nbsp;Cost of sales: 28% to 28.4% of revenues;&nbsp;Restaurant-level EBITDA margin: 20.5% to 21%; G&amp;A: ~$27.1M to $28.5M; Tax rate: ~26% to 28%; Capex: $28M to $30M; Adjusted EPS: $0.76 to $0.80.</li>     <li>DFRG&nbsp;<font color='red'>-2.58%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280237\" data-linked=\"Del Frisco&#39;s Restaurant down on earnings miss and guidance cut\" data-tweet=\"$DFRG - Del Frisco&#39;s Restaurant down on earnings miss and guidance cut https://seekingalpha.com/news/3280237-del-friscos-restaurant-down-on-earnings-miss-and-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3280237-del-friscos-restaurant-down-on-earnings-miss-and-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280228\" data-ts=\"1500636543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLUG\" target=\"_blank\">PLUG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280228-plug-power-up-14-on-new-wal-mart-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plug Power up 14% on new Wal-Mart deal</a></h4><ul><li>The agreement calls for Plug Power (NASDAQ:<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a>) to provide its GenKey hydrogen fuel station and fuel cells to up to 30 additional Wal-Marts (NYSE:<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a>) in North America over the next three years. Ten sites are already under contract and set to be finished this year - the 2017 commitment value should be around $80M.</li><li>Alongside, Wal-Mart has been issued warrants for the purchase of up to 55.3M common shares of Plug. The first set of 5.8M vested on the inking this deal. Additional warrants will vest in installments tied to successive $50M payment thresholds, up to $600M in total.</li><li>PLUG is&nbsp;<font color='green'>higher by 14.15%</font>&nbsp;premarket.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16893037-b-plug-b-power-announces-expanded-collaboration-walmart\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3280228\" data-linked=\"Plug Power up 14% on new Wal-Mart deal\" data-tweet=\"$PLUG $PLUG $WMT - Plug Power up 14% on new Wal-Mart deal https://seekingalpha.com/news/3280228-plug-power-up-14-on-new-wal-mart-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3280228-plug-power-up-14-on-new-wal-mart-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280224\" data-ts=\"1500636387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CL\" target=\"_blank\">CL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280224-colgate-palmolive-lower-post-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Colgate-Palmolive lower post Q2 results</a></h4><ul>     <li>Colgate-Palmolive (NYSE:<a href='https://seekingalpha.com/symbol/CL' title='Colgate-Palmolive Co.'>CL</a>) reports global unit volume declined 1% in <a href=\"https://seekingalpha.com/pr/16893013-colgate-announces-2nd-quarter-2017-results\" target=\"_blank\">Q2</a>.</li>     <li>Organic sales were even Y/Y.</li>     <li>North America net sales dropped 3.7% to $764M.</li>     <li>Latin America net sales rose 6.8% to 1B.</li>     <li>Gross margin rate improved 50 bps to 60.7%, driven by cost savings from the Company&rsquo;s funding-the-growth initiatives and the 2012 Restructuring Program, and higher pricing</li>     <li>SG&amp;A expenses +40 bps to 34.4% of sales.</li>     <li>Operating profit margin decreased 10 bps to 26%.</li>     <li>&ldquo;As we look ahead, uncertainty in global markets and slowing category growth worldwide remain challenging. Based on current spot rates, we continue to expect a low-single-digit net sales increase for 2017, and given our slower than expected first half, we are now planning for low-single-digit organic sales growth for 2017.\" says CEO Ian Cook.</li>     <li>CL&nbsp;<font color='red'>-2.97%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280224\" data-linked=\"Colgate-Palmolive lower post Q2 results\" data-tweet=\"$CL - Colgate-Palmolive lower post Q2 results https://seekingalpha.com/news/3280224-colgate-palmolive-lower-post-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3280224-colgate-palmolive-lower-post-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280223\" data-ts=\"1500636246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEAR\" target=\"_blank\">TEAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280223-tearlab-next-gen-testing-platform-ce-markd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TearLab next-gen testing platform CE Mark&#39;d</a></h4><ul><li>TearLab (NASDAQ:<a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a>) <a href=\"https://seekingalpha.com/pr/16893036-tearlab-announces-european-regulatory-clearance-next-generation-tearlab-discovery-system\" target=\"_blank\">announces </a>that its next-generation in vitro diagnostics testing platform, the TearLab Discovery System, in now CE Mark certified.</li><li>The company says the fully automated lab-on-chip platform enables quantitative measurements of tear proteins on a single nanoliter sample.</li><li>It expects U.S. 510(k) clearance in H2.</li><li><strong>Update</strong>: Investors like the news. Shares are up&nbsp;<font color='green'>75%</font>&nbsp;on almost a 60x surge in volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280223\" data-linked=\"TearLab next-gen testing platform CE Mark&#39;d\" data-tweet=\"$TEAR - TearLab next-gen testing platform CE Mark&#39;d https://seekingalpha.com/news/3280223-tearlab-next-gen-testing-platform-ce-markd?source=tweet\" data-url=\"https://seekingalpha.com/news/3280223-tearlab-next-gen-testing-platform-ce-markd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280222\" data-ts=\"1500635796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNDA\" target=\"_blank\">VNDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280222-european-regulator-rejects-vandas-marketing-application-for-schizophrenia-med-fanaptum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European regulator rejects Vanda&#39;s marketing application for schizophrenia med Fanaptum</a></h4><ul><li>The European Medicine Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; <a href=\"https://seekingalpha.com/pr/16893029-vanda-receives-negative-opinion-marketing-authorization-european-medicines-agency-fanaptum\" target=\"_blank\">adopts a negative opinion</a> against approval of Vanda Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/VNDA' title='Vanda Pharmaceuticals Inc.'>VNDA</a>) Fanaptum (oral iloperidone tablets) for the treatment of adults with schizophrenia saying the benefits do not outweigh the risks. The company intends to appeal the decision.</li><li>It was also rejected in 2012.</li><li>Previously: <a href=\"https://seekingalpha.com/news/721141\" target=\"_blank\">Vanda Pharmaceuticals (VNDA -1.6%) dips after receiving a thumbs down from the European...</a> (Dec. 14, 2012)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280222\" data-linked=\"European regulator rejects Vanda&#39;s marketing application for schizophrenia med Fanaptum\" data-tweet=\"$VNDA - European regulator rejects Vanda&#39;s marketing application for schizophrenia med Fanaptum https://seekingalpha.com/news/3280222-european-regulator-rejects-vandas-marketing-application-for-schizophrenia-med-fanaptum?source=tweet\" data-url=\"https://seekingalpha.com/news/3280222-european-regulator-rejects-vandas-marketing-application-for-schizophrenia-med-fanaptum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280219\" data-ts=\"1500635566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALV\" target=\"_blank\">ALV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280219-autoliv-down-on-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Autoliv down on earnings miss</a></h4><ul>     <li>Autoliv (NYSE:<a href='https://seekingalpha.com/symbol/ALV' title='Autoliv Inc.'>ALV</a>)&nbsp;reports&nbsp;organic sales rose 0.2% in <a href=\"https://www.autoliv.com/Investors/Financial%20Reports/Q22017_e.pdf\" target=\"_blank\">Q2</a>, misses guidance due to lower customer calloffs due to lower than expected light vehicle production in China and North America.</li>     <li>Sales by product: Airbags: $1.316B (+0.1%); Seatbelts: $667.3M (-2.1%);&nbsp;Restraint Control and Sensing: $247.7M (-5.8%); Active safety: $191.2M (+2.8%);&nbsp;Brake Control Systems: $122.2M (-8.3%).</li>     <li>Sales in Asia grew 3.4% (+5.6% organic growth) to $898M.</li>     <li>Sales in America decreased 5.6% (-5.3% organic growth) to $826.5M.</li>     <li>Sales in Europe down 1.7% (+0.5% organic growth) to $820.4M.</li>     <li>Gross profit rate improved 60 bps to 21%.</li>     <li>SG&amp;A expense rate +20 bps to 4.9%</li>     <li>Adjusted operating margin slipped 20 bps to 8.4%</li>     <li><b>Q3 Guidance</b>: Organic sales: 0% to 2%; Adjusted operating margin rate: 7.5% to 8%.</li>     <li><b>FY2017 Guidance</b>: Sales:&nbsp;~+3%;&nbsp;Organic sales: ~+2%; Adjusted operating&nbsp;margin rate: ~8.5%; Tax rate: ~30%; Operational cash flow: more than $0.8B; Capital expenditure: 5% to 6% of total sales.</li>     <li>ALV&nbsp;<font color='red'>-7.08%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280219\" data-linked=\"Autoliv down on earnings miss\" data-tweet=\"$ALV - Autoliv down on earnings miss https://seekingalpha.com/news/3280219-autoliv-down-on-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3280219-autoliv-down-on-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280215\" data-ts=\"1500635125\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCLI\" target=\"_blank\">BCLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280215-brainstorm-nabs-16m-cirm-grant-to-support-late-stage-nurown-study-shares-ahead-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brainstorm nabs $16M CIRM grant to support late-stage NurOwn study; shares ahead 6% premarket</a></h4><ul><li>Brainstorm Cell Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BCLI' title='BrainStorm Cell Therapeutics Inc.'>BCLI</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16892945-brainstorm-awarded-16-million-non-dilutive-grant-cirm-support-phase-3-clinical-trial-nurown\" target=\"_blank\">announcement </a>that the California Institute for Regenerative Medicine &#40;CIRM&#41; has awarded it $16M to support its pivotal Phase 3 clinical trial assessing NurOwn for the treatment of amyotrophic lateral sclerosis &#40;ALS&#41;, also known as Lou Gehrig's disease.</li><li>The study is expected to enroll ~200 patients across six U.S. sites. The primary endpoint will be the ALSFR-S score responder analysis. The patient population will be optimized to include faster-responding patients who demonstrated superior outcomes in the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02017912?term=nurown&amp;cond=Amyotrophic+Lateral+Sclerosis&amp;rank=1\" target=\"_blank\">Phase 2 trial</a>.</li><li><a href=\"http://www.brainstorm-cell.com/index.php/science-technology/nurown%E2%84%A2\" target=\"_blank\">NurOwn&nbsp;</a>cells are mesenchymal stem cells that have been induced, via the company's proprietary methods, to secrete a variety of neurotrophic factors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280215\" data-linked=\"Brainstorm nabs $16M CIRM grant to support late-stage NurOwn study; shares ahead 6% premarket\" data-tweet=\"$BCLI - Brainstorm nabs $16M CIRM grant to support late-stage NurOwn study; shares ahead 6% premarket https://seekingalpha.com/news/3280215-brainstorm-nabs-16m-cirm-grant-to-support-late-stage-nurown-study-shares-ahead-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3280215-brainstorm-nabs-16m-cirm-grant-to-support-late-stage-nurown-study-shares-ahead-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM </div></div></li>","count":53,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}